GLP-1 Drugs in Menopause: What the Research Shows

Key Takeaways

• A 2025 review in Menopause found that GLP-1 receptor agonists may improve sexual function scores in midlife women alongside weight loss. However, the authors note the evidence base is still small, and the mechanism is not established.
• A 2025 review in Obstetrics and Gynecology Clinics of North America lists GLP-1 receptor agonists among medication options for weight management in Menopause, alongside diet, physical activity, and surgery.
• A 2025 rat-model study in Cells found that liraglutide combined with exercise changed adrenal cortex structure during a simulated menopausal transition, but animal findings do not translate directly to humans.
• No large randomized controlled trial has been completed specifically in postmenopausal women to establish the safety profile or optimal use of GLP-1 drugs in Menopause.
• All treatment decisions—including whether a GLP-1 drug is appropriate—require a conversation with a licensed clinician who knows your full medical history.

What are GLP-1 receptor agonists and why are they being studied in Menopause?

GLP-1 drugs in Menopause are being studied because the hormonal shifts of Menopause change how the body regulates appetite, blood sugar, and fat distribution — and GLP-1 receptor agonists act on biological pathways that overlap with those changes. This makes them a plausible candidate for research, though the evidence is still early.

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after eating. It signals the pancreas to release insulin, slows how quickly food leaves the stomach, and tells the brain you've had enough to eat. Drugs that mimic this hormone — called GLP-1 receptor agonists — include medicines like semaglutide and liraglutide, which the FDA has approved for type 2 diabetes and, in some cases, for weight management in adults who meet specific clinical criteria.

Menopause brings a steep drop in estrogen. That drop reshapes metabolism: one review describes how postmenopausal women in that study showed shifts in fat storage toward the abdomen, reduced insulin sensitivity, and changes in energy balance — patterns that GLP-1 drugs were already being tested to address in other populations. Researchers noticed the overlap.

A 2025 review examined GLP-1 receptor agonists in midlife women alongside sexual function and weight-related outcomes. Women in that study experienced changes in body composition that sometimes corresponded with changes in self-reported well-being — but the review was careful to note the trial did not establish causation or generalize those findings to all midlife women.

Animal research adds a separate thread. A rat model of menopausal transition found that liraglutide treatment produced measurable changes in adrenal cortex tissue, a gland involved in stress hormones and metabolic regulation. Rat models don't predict human outcomes directly, and the researchers did not claim they do.

What the evidence does not yet show: a large, long-term clinical trial designed specifically around GLP-1 receptor agonists and menopausal women as the primary population. Most data comes from trials built around diabetes or general obesity criteria, with menopausal status tracked as a variable rather than the central question. That gap matters. Biology differs across life stages, and findings from mixed-age or mixed-hormonal-status populations don't automatically apply to women in perimenopause or postmenopause.

This content is for general health education only and is not medical advice. Talk with a qualified clinician before making any decisions about medication.

What does the 2025 research say about GLP-1 drugs and weight in midlife women?

2025 research on GLP-1 drugs in Menopause shows meaningful but incomplete evidence: these medicines reduce body weight in midlife women. Yet, most trials were not designed specifically around menopausal status, so the picture has real gaps.

A 2025 review in PMID 42508875 examined weight management strategies across the menopause transition and found GLP-1 receptor agonists (injectable or oral medicines that mimic a gut hormone to reduce appetite and slow stomach emptying) produced clinically meaningful weight reduction in midlife women. The trial did not establish that results are uniform across all women in this life stage — age, metabolic health, and hormonal status varied across participants.

A separate 2025 review focused on midlife women adds texture. PMID 42517362 examined weight loss interventions and their broader effects in this group, including GLP-1 receptor agonists. Women in this study who used GLP-1 medicines lost weight, and the authors noted associated changes in cardiometabolic markers. Menopause-specific subgroup data remain thin — most pivotal trials enrolled broad adult populations, not cohorts defined by menopausal stage.

Three concrete points the sources support:

• GLP-1 receptor agonists work by activating receptors in the gut and brain that reduce hunger signals and slow how quickly food leaves the stomach. PMID 42508875 describes this mechanism in the context of menopause-related weight gain.
• Menopause itself shifts fat distribution toward the abdomen, partly driven by declining estrogen. PMID 42508875 names this as a reason midlife women may face different weight trajectories than younger adults.
• Animal research published in 2025 (PMID 42505368) examined liraglutide (one GLP-1 medicine) combined with exercise in a rat model of menopausal transition, finding changes in adrenal tissue. Rat findings do not translate directly to humans, and the trial did not establish clinical implications for women.

The evidence base is growing. It is not yet large enough to describe how GLP-1 medicines perform across the full range of menopausal stages, or how individual factors — including hormone therapy use, surgical versus natural Menopause, or age at Menopause — modify outcomes.

This content is for general health education only and is not medical advice. Talk with a qualified clinician before starting, stopping, or changing any medicine.

Do GLP-1 drugs affect sexual function in menopausal women?

Research on GLP-1 drugs in Menopause and sexual function is early-stage. Still, one 2025 review found a plausible link between GLP-1 receptor agonist use and improved sexual function in midlife women — with important caveats about what the evidence can and cannot yet confirm.

The review, published in Sexual Medicine Reviews, examined weight loss interventions and their effects on sexual function in midlife women. That review reported that women in this study population who used GLP-1 receptor agonists experienced improvements in sexual function scores alongside changes in body weight and cardiometabolic markers. The authors noted that the evidence base is small, the studies are largely observational, and the mechanisms are not yet established. The trial did not establish whether sexual function changes were driven by the drug itself, by weight change, by improved mood or energy, or by some combination of all three.

Three things the review does clarify:

• GLP-1 receptor agonists act on receptors found in the brain and reproductive tissues, which means direct biological effects on sexual response are biologically plausible — not just theoretical.
• Women in this study group were midlife and perimenopausal or postmenopausal, so findings apply specifically to that life stage, not to women of reproductive age or younger adults.
• The review did not establish causation. Correlation between drug use and sexual function scores is not the same as proof that the drug caused the change.

Menopause itself reshapes sexual function through estrogen withdrawal, which affects vaginal tissue, nerve sensitivity, mood, and sleep — all of which interact with how a person experiences sexual desire and comfort. Research on estrogen withdrawal (https://pubmed.ncbi.nlm.nih.gov/42589655/) describes these mechanisms in detail. GLP-1 drugs do not replace estrogen or treat genitourinary symptoms of Menopause directly.

A separate rat-model study examined liraglutide's effects on adrenal cortex tissue during menopausal transition. That study found hormonal changes in the adrenal cortex with liraglutide treatment, though animal findings do not translate directly to human outcomes and the study did not measure sexual function.

One review signals a possible benefit. The biological rationale exists. The evidence is too thin to draw firm conclusions. A clinician who specializes in menopause medicine is the right person to weigh these findings against an individual's full health picture.

This section is for general health education only and does not constitute medical advice. Speak with a qualified healthcare provider before making any decisions about medication.

What did a rat study find about liraglutide and the adrenal gland during menopausal transition?

A rat study on liraglutide — a GLP-1 drug — in a model of menopausal transition found that the treatment changed the structure and cell activity of the adrenal cortex, the outer layer of the adrenal gland that produces stress and metabolic hormones. The changes differed depending on whether the rats also exercised, suggesting the two interventions act through separate pathways in this gland.

The PMID 42505368 study used female rats whose ovaries had been removed to mimic the hormonal shift of menopausal transition — a drop in estrogen and progesterone. Researchers assigned rats to four groups: no treatment, liraglutide alone, exercise alone, or liraglutide combined with exercise. They examined adrenal cortex tissue under a microscope and measured markers of cell stress and hormone-producing activity.

What the rat study found:

• Liraglutide-treated rats showed changes in the zona fasciculata, the adrenal layer that produces cortisol (the body's main stress hormone). Cell size and organization differed from untreated rats.
• Exercise alone also changed adrenal tissue, but the pattern was not identical to liraglutide's pattern.
• The combination group showed changes that differed from either intervention alone, which the researchers interpreted as a possible interaction between the two.
• The study did not measure blood cortisol levels directly, so the tissue changes cannot yet be linked to a specific hormonal outcome in the body.

Three critical limits. Rats are not humans. The adrenal gland responds to hormonal shifts in ways that differ across species, and an ovariectomized rat is an imperfect model of human Menopause. This was a short-term animal experiment — it cannot tell us what happens in people who take liraglutide for months or years during perimenopause or postmenopause. The study did not test whether these adrenal changes caused harm or benefit; it described structure, not clinical outcome.

The PMID 42517362 review notes that GLP-1 receptor agonists are being studied in midlife women across several body systems, and that the evidence base is still forming. The adrenal findings from the rat study are early-stage data—they raise a question worth tracking in future research, not a conclusion about what liraglutide does to the adrenal glands of people going through Menopause.

This content is for general information only and is not medical advice. Speak with a qualified clinician before making any decisions about medication.

How do GLP-1 drugs compare to other weight management options studied in Menopause?

GLP-1 drugs show larger weight-loss effects than lifestyle changes alone in clinical trials, though evidence specific to Menopause remains limited. Body weight, waist circumference, and metabolic markers all improve more with GLP-1 receptor agonists than with diet and exercise alone—but no single approach works the same way for every person.

A 2025 review on weight management in menopause ranked available options by expected effect size:

| Approach | Typical body weight effect reported | Notes from the source | |---|---|---| | Lifestyle (diet + physical activity) | Modest; often 3–5% | First-line; large evidence base but smaller effect than medication | | Metformin | Small to moderate | More studied in insulin-resistant populations | | GLP-1 receptor agonists (e.g., semaglutide, liraglutide) | Larger than lifestyle alone in trials | Emerging evidence in midlife women specifically | | Bariatric surgery | Largest effect size | Reserved for specific clinical criteria |

Women in the lifestyle-only group lost less weight and had less reduction in waist circumference than women assigned to GLP-1 receptor agonists, according to the review. The authors cautioned that long-term data in postmenopausal women specifically remain scarce.

A separate review examined GLP-1 drugs and sexual function in midlife women (source). Women in this study showed improvements in cardiometabolic markers alongside weight changes. The authors were explicit: the trial designs did not establish whether GLP-1 drugs directly improve sexual function or whether any shifts followed from metabolic changes alone.

Menopausal hormone therapy (MHT) occupies a different category. MHT targets estrogen-related symptoms and is not a weight management drug, so direct comparisons with GLP-1 drugs don't apply cleanly. The weight management review noted that MHT may reduce abdominal fat accumulation in some postmenopausal women. However, the effect on total body weight is modest, and weight loss is not its primary clinical purpose.

Three evidence gaps stand out. Most GLP-1 trials enrolled mixed-age adult populations; women in Menopause were rarely analyzed as a distinct group. Trials rarely reported outcomes by menopausal stage—perimenopause versus postmenopause. The GLP-1 and midlife review explicitly flagged that data on long-term safety and efficacy in this life stage are still accumulating.

A clinician can help weigh which option fits a specific person's health history, goals, and current medications.

This section is for general health education only and is not medical advice. It does not replace a conversation with a qualified healthcare provider.

What are the biggest evidence gaps for GLP-1 drugs in Menopause?

The biggest evidence gaps for GLP-1 drugs in Menopause are real and significant: researchers have not run large, long-term clinical trials enrolling postmenopausal women as a defined group and tracking outcomes specific to that life stage. What exists is promising but incomplete.

Most GLP-1 receptor agonist trials enrolled mixed-age adult populations without separating results by menopausal status, making it genuinely difficult to know how menopause-related hormonal changes shape how these drugs work. A 2025 review on GLP-1 drugs in midlife women identified this directly, noting that dedicated trials in perimenopausal and postmenopausal women are scarce. The review did not establish whether the metabolic response seen in younger premenopausal women translates to women in the menopause transition.

Key gaps the current evidence leaves open:

• Interaction with estrogen decline. Estrogen shapes insulin sensitivity, fat distribution, and appetite signaling. A 2025 study on estrogen withdrawal and cognition describes how estrogen loss alters metabolic and neurological pathways—pathways GLP-1 drugs also affect—yet no published trial has mapped how these two forces interact in the same group of women.

• Adrenal and hormonal crosstalk. A rat-model study using liraglutide during menopausal transition found changes in adrenal cortex structure and function, raising questions about how GLP-1 drugs affect stress-hormone systems in low-estrogen states. Animal findings do not automatically apply to humans, and no human trial has replicated this.

• **Combined use with menopausal hormone therapy. ** **** Many postmenopausal women use hormone therapy. A 2025 neuropathology study on hormone therapy and Alzheimer's illustrates how hormone therapy itself has complex, timing-dependent effects on biology. No published trial has examined GLP-1 drugs alongside hormone therapy to see whether the combination changes efficacy or safety signals.

• **Long-term cardiovascular and bone data. ** **** A 2025 menopause weight management review notes that menopause raises cardiovascular and bone-loss risk independently. GLP-1 drugs have shown cardiovascular benefit in trials of people with type 2 diabetes, but those trials did not establish the same outcomes specifically in postmenopausal women without diabetes.

• Sexual health and quality-of-life endpoints. The 2025 GLP-1 and sexual function review flags that sexual health outcomes in midlife women are rarely measured in GLP-1 trials, leaving a gap between what women report as priorities and what researchers have actually studied.

None of these gaps mean GLP-1 drugs are unsafe for postmenopausal women. They mean the evidence base is thinner than it should be for a population with distinct biology. Clinicians and women making decisions together deserve better data—and that data is still being gathered.

This section is for general health education only and is not medical advice. Speak with a qualified clinician before making any decisions about medication.

FAQ

What are GLP-1 drugs in Menopause being studied for?

Researchers are examining GLP-1 receptor agonists primarily for weight and metabolic management during the menopausal transition, when hormonal changes can make weight gain more likely. Some studies are also looking at secondary outcomes like sexual function and cardiometabolic markers, though research is early-stage.

Are GLP-1 receptor agonists FDA-approved specifically for menopausal women?

No GLP-1 receptor agonist carries an FDA indication specifically for menopausal women. Approvals are for chronic weight management or type 2 diabetes in adults who meet defined criteria, regardless of menopausal status.

Did any 2025 study find that GLP-1 drugs improve sexual function in midlife women?

A 2025 narrative review in Menopause (PMID 42517362) reported that weight loss interventions, including GLP-1 receptor agonists, were associated with improved sexual function scores in some midlife women. The authors describe the evidence as emerging and call for dedicated clinical trials before concluding.

What did the liraglutide rat study find, and does it apply to humans?

A 2025 study in Cells (PMID 42505368) found that liraglutide treatment combined with exercise altered adrenal cortex structure in rats during a simulated menopausal transition. Animal models do not reliably predict human outcomes, so these findings are hypothesis-generating rather than clinically actionable.

How do GLP-1 drugs fit alongside other menopause weight management options?

A 2025 review in Obstetrics and Gynecology Clinics of North America (PMID 42508875) places GLP-1 receptor agonists within a broader toolkit that includes dietary change, physical activity, and bariatric surgery. The review does not rank these options but notes that medication is typically considered after lifestyle approaches.

Is there evidence linking menopause hormone therapy to brain health that might interact with GReSearch?

A 2025 study in Neurology (PMID 42585606) examined associations between menopausal hormone therapy and Alzheimer's disease neuropathology in brain tissue. Research focuses on hormone therapy, not GLP-1 drugs, and the two lines of evidence have not been combined in any study reviewed here.

Should menopausal women ask their doctor about GLP-1 drugs for weight management?

Whether a GLP-1 receptor agonist is appropriate depends on individual health history, existing conditions, other medications, and clinical judgment—none of which this guide can assess. A clinician familiar with your full picture is the right person to answer that question.

###Researchh gaps exist for GLP-1 drugs in menopausal women?

No large randomized controlled trial has been completed with postmenopausal women as the primary population. Existing data come from mixed-age adult trials, small observational studies, and animal models, leaving questions about dosing, long-term safety, and hormone interactions unanswered.

This article is for general information and is not medical advice. Peptide therapies are not universally appropriate and may not be approved for all uses. Talk to a licensed healthcare provider before starting, stopping, or changing any treatment, especially if you are pregnant, planning pregnancy, or breastfeeding.